Beijing News News According to the Micro News of China Biological Officials, on May 9, sinopharm Group China Biological Beijing Institute of Biological Products Aomi Kerong strain (hereinafter referred to as Ao strain) new crown virus inactivated vaccine sequential clinical trial was launched in Hunan Province. This is the first time that a sequential clinical study of the OVAR vaccine has been carried out in a population that has been vaccinated against THE NEW CROWN after the launch of the chinese bio-ovum vaccine in Hangzhou, Zhejiang Province on May 1.
Yang Xiaoming, Chairman of China Biologics, Zhu Jingjin, Secretary of the Party Committee and Vice President, Zhang Yuntao, Chief Scientist and Vice President, and Yang Yunkai, Deputy Director of Clinical Medical Center, attended the kick-off meeting of the sequential clinical trial of the New Coronavirus vaccine at the Beijing venue.
This is currently the world's first sequential clinical sequence of the largest number of people, the earliest launch, and the comprehensive design of the Omiljun strain inactivated vaccine for the new crown virus.
The clinical study was designed as a randomized, double-blind, controlled study to evaluate the safety and immunogenicity of the inactivated covid-19 vaccine of the Aumechjong strain inactivated COVID-19 vaccine in 18 years of age and older who have been vaccinated with 2 or 3 doses of the new crown virus vaccine at different intervals and in different orders.
▲Yang Xiaoming, chief engineer of Sinopharm Group and chairman of China Biologics
Yang Xiaoming said in his speech that since the outbreak of the epidemic, Sinopharm China Biologics has paid close attention to the changes in the epidemic, scientific analysis, comprehensive research and judgment, and laid out teams such as Beijing Institute of Biological Products, Wuhan Institute of Biological Products, China Institute of Biological Products, and Zhongsheng Funuojian in advance, and promoted the research and development of 4 vaccines on 3 technical routes day and night. On the basis of the previously listed prototype strain of the new crown inactivated vaccine, the First Time from the University of Hong Kong introduced the Aumecreon variant strain, and the research and development of the Austrian strain vaccine was rapidly launched on December 9, 2021, and the clinical study launched today will evaluate the safety and immunogenicity of the vaccine in humans.
▲Zhang Yuntao, chief scientist and vice president of China Biology
Zhang Yuntao said that China Biologics has systematically completed the preclinical study of the inactivated vaccine of the new crown of the Austrian strain, and carried out in vitro cross-neutralization experiments with various new crown variants. The results of the study show that the New Crown vaccine can produce high-titer neutralizing antibodies against both the Strain and a variety of variant strains. This clinical study plans to enroll more than 4,000 people, which will evaluate the immunogenicity and safety of the New Coronavirus vaccination of the Austrian strain, and observe the best immunization procedures and doses in the future, which is currently the world's largest clinical study of the new crown vaccine against the Austrian strain. Participating in the clinical research site has carried out clinical research on the new crown vaccine listed by China Biology for special populations of hypertension/diabetes, and the experience accumulated in the early stage has laid a solid foundation for the clinical research of Ao zhu. I hope that we will continue to deepen cooperation, go one step further, and fully and efficiently complete the clinical trial of the new crown vaccine of Aoluo.
On April 12, two inactivated vaccines of the new coronavirus developed by China Bio-Beijing Institute of Biological Products and Wuhan Institute of Biological Products were approved by the University of Hong Kong and the Ethics Committee of the Hong Kong Island West Hospital Network research, and on April 13, they were approved by the Clinical Trial Approval of the Hong Kong Pharmacy and Poisons Authority, and were officially approved to carry out sequential immune clinical research on the new crown vaccine in Hong Kong. On April 26, the inactivated vaccine of the new coronavirus of China Biological Beijing Institute of Biological Products was approved by the State Food and Drug Administration for clinical trials.
On April 29, two inactivated vaccines of the new coronavirus of China Biologics Beijing and the Wuhan Institute of Biological Products, and the recombinant new crown vaccines developed by the Sinopharm Institute of Biotechnology of China Medicine/National Engineering Research Center for New Vaccines, a total of three New Coronavirus vaccines were approved by the Ministry of Health of Abu Dhabi, United Arab Emirates. This is an important progress in the international multi-center clinical trial of the New Crown Vaccine of China Bio-Olympic Strain.
On May 1, the clinical study of the Ao zhu new crown vaccine in the blank population of the Beijing Institute of Biological Products of China Biologics was officially launched in Hangzhou, Zhejiang Province. The Chinese Bio-Olays new crown vaccine has thus become the world's first inactivated covid-19 vaccine against the Omiljung strain that has entered clinical trials.
Next, China Biologics will actively and efficiently promote the international multi-center clinical trial of the Austrian new crown vaccine in various technical routes, so that the vaccine can benefit the Chinese people and the global people as soon as possible, and contribute more Chinese strength to the joint construction of a human health community!
Edited by Linzhi Sun